PLC Systems
This article was originally published in The Gray Sheet
Executive Summary
Proposed offering should enable the firm to meet cash requirements through the end of 1993. The Milford, Massachusetts-based company plans to use the $1.4 mil. in expected net proceeds for costs associated with premarket approval of its Heart Laser, a laser system for transmyocardial revascularization ("The Gray Sheet" June 22, 1992, p. 17). Of the 850,534 shares registered on Feb. 12 with the Securities and Exchange Commission, 765,844 will be offered by stockholders. The remaining 84,699 shares are issuable upon the exercise of warrants granted in an August 1992 bridge financing. The estimated $1.4 mil. in proceeds will be realized via the exercise of the warrants and upon payment of promissory notes that were issued in connection with the warrants.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.